论文部分内容阅读
目的 探讨nm23蛋白在骨巨细胞瘤(GCT)的表达及其与GCT病理分级和复发的关系。方法 应用SP免疫组织化学方法检测nm23在52例GCT(按Jaffe分级：Ⅰ级15例、Ⅱ级25例、Ⅲ级12例)中的表达。 结果 21例nm23表达呈阳性，总阳性率为40.4%，在Ⅰ级、Ⅱ级、Ⅲ级中的阳性表达率分别为33.3%、44.0%、41.7%，nm23阳性表达在骨巨细胞瘤Ⅰ级、Ⅱ级、Ⅲ级中差异无显著性(χ2=0.45，P>0.05)。在术后3年内出现复发的13例中，有9例阳性表达，无复发的39例中有12例阳性表达，两者差异显著(χ2=5.99，P<0.05)。结论 nm23在GCT中的表达与病理分级无关，但与其复发有关。
Objective To investigate the expression of nm23 protein in giant cell tumor of bone (GCT) and its relationship with the grading and recurrence of GCT. Methods SP immunohistochemistry was used to detect the expression of nm23 in 52 cases of GCT (according to Jaffe classification: Ⅰ grade 15 cases, Ⅱ grade 25 cases, Ⅲ grade 12 cases). Results The positive expression rate of nm23 in 21 cases was 40.4%. The positive expression rates of nm23 in grades Ⅰ, Ⅱ and Ⅲ were 33.3%, 44.0% and 41.7%, respectively. The positive expressions of nm23 in grade Ⅰ, , Grade Ⅱ, grade Ⅲ in the difference was not significant (χ2 = 0.45, P> 0.05). Of the 13 cases with recurrence within 3 years after operation, 9 were positive, and 12 of 39 without recurrence were positive (χ2 = 5.99, P <0.05). Conclusion The expression of nm23 in GCT has nothing to do with the pathological grade, but it is related to its recurrence.